COGSTATE LIMITED (CGS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CGS

CGS - COGSTATE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.03
Index: ALL-ORDS | ALL-TECH

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.37

19 Feb
2026

0.190

OPEN

$2.32

8.72%

HIGH

$2.37

47,679

LOW

$2.14

TARGET
$2.90 22.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
CGS: 1
Title FY26
Forecast
FY27
Forecast
EPS (cps) 9.5 xxx
DPS (cps) 3.1 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 22.9 xxx
Dividend Yield 1.4% xxx
Div Pay Ratio(%) 32.3% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.23%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.92

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx9.2
DPS All xxxxxxxxxxxxxxx2.0
Sales/Revenue xxxxxxxxxxxxxxx82.0 M
Book Value Per Share xxxxxxxxxxxxxxx43.3
Net Operating Cash Flow xxxxxxxxxxxxxxx19.0 M
Net Profit Margin xxxxxxxxxxxxxxx19.11 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx23.32 %
Return on Invested Capital xxxxxxxxxxxxxxx23.11 %
Return on Assets xxxxxxxxxxxxxxx16.89 %
Return on Equity xxxxxxxxxxxxxxx23.32 %
Return on Total Capital xxxxxxxxxxxxxxx29.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx18.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx54 M
Price To Book Value xxxxxxxxxxxxxxx4.03

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx4.7 M
Capex % of Sales xxxxxxxxxxxxxxx5.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx51 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

20/02/2026

1

Buy

$2.90

22.36%

Bell Potter notes Cogstate’s 1H26 revenue was pre-released and EBIT of $4.9m was 7% ahead of expectations due to lower operating expenses, with the EBIT margin of 18.3% above guidance.

Gross margin was temporarily reduced by additional hiring, cost reallocation and a doubtful debt provision, but EBITDA still rose 5% and NPAT up 16% due to a lower tax outcome.

Bell Potter highlights a strong balance sheet with $34.1m cash and no debt, alongside record pipeline opportunities, record new trial starts, and a $16.0m increase in backlog after $41.7m of new sales.

Management's FY26 guidance was broadly in line, including expectations for stronger 2H26 revenue, gross margin recovery to 56-59%, and continued operating leverage with channel partnerships expanding opportunities.

Bell Potter retains Buy and keeps its target price at $2.90, lifsting NPAT forecasts 2% for both FY27/FY28 with FY26 unchanged.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 3.06 cents and EPS of 9.49 cents.
Bell Potter forecasts a full year FY27 dividend of 3.83 cents and EPS of 11.47 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

15/12/2025

1

Buy

$3.30

39.24%

Canaccord Genuity initially considered Cogstate's 1H26 update as a downgrade, but later observed the weaker recognised revenue/margins largely reflect timing and mix in a contract-based model. It is not a change in underlying demand, the broker concluded.

Contracted revenue was strong at US$37-40m, and the broker expects the FY26 revenue shortfall to be recovered in 2H with only minor earnings impact.

Gross margin may come in -1-2pp below the 61% FY26 forecast, pressuring earnings slightly, while higher staff costs are already expected. 

AI rollout is expected to drive OpEx efficiencies over the next 12–18 months as the business shifts toward more service-heavy trial work.

Buy. Target unchanged at $3.30.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 1.84 cents and EPS of 8.87 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 3.52 cents and EPS of 11.63 cents.

CGS STOCK CHART